Advances in long-acting recombinant factor Ⅸ for the treatment of hemophilia B.
10.3760/cma.j.issn.0253-2727.2022.03.014
- Author:
Xi Yan WANG
1
;
Ren Chi YANG
1
Author Information
1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laborator of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin 300020, China.
- Publication Type:Journal Article
- MeSH:
Factor IX/therapeutic use*;
Factor VIII;
Hemophilia A/drug therapy*;
Hemophilia B/drug therapy*;
Humans;
Recombinant Proteins/therapeutic use*
- From:
Chinese Journal of Hematology
2022;43(3):259-264
- CountryChina
- Language:Chinese
